Mind Medicine - MNMD STOCK NEWS

MindMed (NASDAQ: MNMD) has announced its participation in the Digital Medicine Society's Digital Health Measurement Collaborative Community (DATAcc), aimed at developing best practices for digital health measurement. The initiative includes leaders from government, non-profit, and private sectors, including the FDA. MindMed's Chief Medical Officer, Dan Karlin, emphasized the importance of real-world data in understanding mental health conditions. The collaborative will focus on areas such as data governance and digital inclusion, striving to enhance health outcomes and equity.

MindMed (NASDAQ: MNMD), a leading biotech firm focused on psychedelic-inspired therapies, announced that CEO Robert Barrow will host a roundtable at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13, 2021, from 4:15-5:00 PM ET. A live audio webcast will be accessible in the "Investors" section of MindMed's website, with a replay available for 30 days. MindMed is committed to developing innovative medications for addiction and mental health disorders using substances like psilocybin and LSD.

MindMed (NASDAQ: MNMD) announced a partnership with Datavant to utilize its data-linking technology for clinical trials. This will enhance MindMed's ability to connect its clinical data to external sources, improving insights into psychiatric and substance use disorders. The collaboration aims to create detailed datasets to refine clinical planning and commercialization. This initiative supports MindMed's goal of developing psychedelic-inspired therapies, potentially transforming mental health treatment.

MindMed has been included in the FTSE Russell 3000 Index as of June 25, 2021. This index tracks the performance of the 3,000 largest US companies, and inclusion signifies a notable recognition for MindMed in the market. The Russell indexes are widely used by institutional investors and manage approximately $10.6 trillion in assets. CEO Robert Barrow highlighted this achievement as a reflection of the company's progress towards its goals in mental health and addiction treatment. Membership aids in enhancing the visibility and credibility of MindMed among investors.

MindMed (Nasdaq: MNMD) has appointed Dr. Maurizio Fava to its Scientific Advisory Board. Dr. Fava, a leading psychiatrist from Massachusetts General Hospital and Harvard Medical School, brings extensive experience, having founded the hospital's Depression Clinical and Research Program and the Psychiatry Clinical Trials Network. With over $120 million in research funding and involvement in significant studies, his expertise is expected to enhance MindMed's development of psychedelic-inspired therapies. CEO Robert Barrow expressed enthusiasm for Dr. Fava's contributions to the company's mission.

MindMed (NASDAQ: MNMD) has appointed Dr. Peter Bergethon to its Scientific Advisory Board. Dr. Bergethon, Vice President at Biogen, brings expertise in neurology and digital medicine, aiming to enhance MindMed's efforts in developing psychedelic-inspired therapies for mental health and addiction. His background includes senior roles at Pfizer and academic positions at Boston and Tufts Universities. CEO Robert Barrow expressed confidence in Dr. Bergethon's ability to contribute to groundbreaking research and public health impacts as MindMed progresses in improving mental health treatment.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announces the resignation of J.R. Rahn as CEO, effective immediately, with Robert Barrow taking over the role. Barrow, previously the company's Chief Development Officer, has extensive experience in pharmaceutical development and will lead the firm into later stage clinical trials. MindMed raised over US$204 million under Rahn, establishing itself as a leader in the psychedelic medicine sector. The transition aims to strengthen the company’s drug development initiatives and digital medicine strategies.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that all resolutions at the annual shareholder meeting held on May 27, 2021, were approved by requisite majorities. Notable outcomes include the re-election of six directors and the addition of Dr. Sarah Vinson, bringing the total to seven directors. Shareholders also approved the appointment of RSM Canada LLP as auditor and amendments to the Company's articles. Approximately 39.52% of shares were voted, highlighting strong shareholder engagement. CEO J.R. Rahn emphasized the importance of ongoing dialogue with shareholders.

MindMed (Nasdaq: MNMD), a psychedelic medicine biotech firm, has published the first pharmacogenetic data on LSD, which may help personalize dosing for patients. The study analyzed data from four Phase 1 trials conducted at the University Hospital Basel, revealing that genetic factors, especially CYP2D6 variations, significantly influence LSD metabolism and its psychological effects. The findings suggest that metabolic testing can inform individual LSD dosing. This research is a critical step in developing LSD as a medication, emphasizing the need for tailored patient treatment.